Koers Adynxx, Inc. Other OTC
Aandelen
ADYX
US00784D1037
Biotechnologie & Medisch Onderzoek
Omzet 2017 | - | Omzet 2018 | - | Marktkapitalisatie | 5 4,67 |
---|---|---|---|---|---|
Nettowinst (verlies) 2017 | -11 mln. -10,27 mln. | Nettowinst (verlies) 2018 | -5 mln. -4,67 mln. | EV/omzet 2017 * | - |
Nettoliquiditeiten 2017 * | - 0 | Nettoliquiditeiten 2018 * | - 0 | EV/omzet 2018 * | - |
K/w-verhouding 2017 * |
-
| K/w-verhouding 2018 * |
-
| Werknemers | - |
Dividendrendement 2017 * |
-
| Dividendrendement 2018 * |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Julien Mamet
FOU | Founder | - | 01-10-07 |
Rick Orr
CEO | Chief Executive Officer | - | 01-12-10 |
Dina Gonzalez
DFI | Director of Finance/CFO | - | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eckard Weber
BRD | Director/Board Member | 73 | - |
Stanley Abel
BRD | Director/Board Member | - | 01-01-08 |
Dennis Podlesak
CHM | Chairman | 66 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,41% | 45,51 mld. | |
+38,65% | 39,36 mld. | |
-8,62% | 38,52 mld. | |
+26,95% | 30,74 mld. | |
-13,50% | 26,03 mld. | |
+10,74% | 25,92 mld. | |
+44,87% | 14,13 mld. | |
+34,36% | 12,73 mld. | |
-7,14% | 11,29 mld. |